Generic placeholder image

Current Radiopharmaceuticals

Author(s): Haohao Lu, Chuansheng Zheng*, Bin Liang and Xiangwen Xia

DOI: 10.2174/0118744710261186231026062257

DownloadDownload PDF Flyer Cite As
Analysis of the Efficacy and Safety of Palonosetron Hydrochloride in Preventing Nausea And Vomiting After TACE: A Retrospective Analysis

Page: [46 - 54] Pages: 9

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Purpose: To investigate the mechanism of nausea and vomiting after TACE, and analyze the efficacy and safety of palonosetron hydrochloride in the prevention of nausea and vomiting after TACE.

Methods: The data of 221 patients who underwent TACE in the Department of Intervention Therapy from August 2018 to August 2020 were collected. The patients were divided into two groups: those who did not use palonosetron hydrochloride before TACE (TACE group, N=116); and those who used palonosetron hydrochloride before TACE (TACE+palonosetron group, N=105). Primary study endpoint: The control rate of nausea and vomiting in the two groups at 0-24 h (acute), 24-120 h (delayed), and 0-120 h. Secondary Study Endpoints: Adverse events of palonosetron hydrochloride.

Results: TACE group vs TACE+palonosetron group: 0-24 h, 74 vs. 44 patients with nausea (63.8% vs. 41.9%); 24-120 h, 50 vs. 16 patients with nausea (43.1% vs. 15.2%); 0-120 h after TACE, 81 vs. 50 patients with nausea (69.8% vs. 47.6%). 0-24 h, 52 vs. 26 patients with vomiting (44.8% vs. 24.8%); 24-120 h, 24 vs. 8 patients with vomiting (20.7% vs. 7.6%); 0-120 h after TACE, 64 vs. 26 patients with vomiting (55.2% vs. 24.8%). The incidence of nausea and vomiting after TACE was significantly lower in the TACE+palonosetron group than in the TACE group (p < 0.05).

Conclusion: Palonosetron hydrochloride can significantly reduce the incidence of nausea and vomiting in patients after TACE, with exact effect and high safety.

Graphical Abstract

[1]
Wallace, M.C.; Preen, D.; Jeffrey, G.P.; Adams, L.A. The evolving epidemiology of hepatocellular carcinoma: A global perspective. Expert Rev. Gastroenterol. Hepatol., 2015, 9(6), 765-779.
[http://dx.doi.org/10.1586/17474124.2015.1028363] [PMID: 25827821]
[2]
Chonprasertsuk, S.; Vilaichone, R. Epidemiology and treatment of hepatocellular carcinoma in Thailand. Jpn. J. Clin. Oncol., 2017, 47(4), 294-297.
[http://dx.doi.org/10.1093/jjco/hyw197] [PMID: 28042136]
[3]
Testino, G.; Leone, S.; Patussi, V.; Scafato, E.; Borro, P. Hepatocellular carcinoma: Diagnosis and proposal of treatment. Minerva Med., 2016, 107(6), 413-426.
[PMID: 27353771]
[4]
Budny, A.; Kozłowski, P; Kamińska, M; Jankiewicz, M; Kolak, A; Budny, B; Budny, W; Niemunis-Sawicka, J; Szczypiór, G; Kurniawka, B; Burdan, F Epidemiology and risk factors of hepatocellular carcinoma. Pol. Merkur Lekarski., 2017, 43(255), 133-139.
[5]
Raoul, J.L.; Forner, A.; Bolondi, L.; Cheung, T.T.; Kloeckner, R.; de Baere, T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat. Rev., 2019, 72, 28-36.
[http://dx.doi.org/10.1016/j.ctrv.2018.11.002] [PMID: 30447470]
[6]
Bannangkoon, K.; Hongsakul, K.; Tubtawee, T.; Mc Neil, E.; Sriplung, H.; Chongsuwiwatvong, V. Rate and predictive factors for sustained complete response after selective transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Asian Pac. J. Cancer Prev., 2018, 19(12), 3545-3550.
[http://dx.doi.org/10.31557/APJCP.2018.19.12.3545] [PMID: 30583681]
[7]
Han, T.; Yang, X.; Zhang, Y.; Li, G.; Liu, L.; Chen, T.; Zheng, Z. The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis. Biosci. Trends, 2019, 13(5), 374-381.
[http://dx.doi.org/10.5582/bst.2019.01153] [PMID: 31611486]
[8]
Blackburn, H.; West, S. Management of postembolization syndrome following hepatic transarterial chemoembolization for primary or metastatic liver cancer. Cancer Nurs., 2016, 39(5), E1-E18.
[http://dx.doi.org/10.1097/NCC.0000000000000302] [PMID: 26484962]
[9]
Agrawal, R.; Majeed, M.; Aqeel, S.B.; Wang, Y.; Haque, Z.; Omar, Y.A.; Upadhyay, S.B.; Gast, T.; Attar, B.M.; Gandhi, S. Identifying predictors and evaluating the role of steroids in the prevention of post-embolization syndrome after transarterial chemoembolization and bland embolization. Ann. Gastroenterol., 2020, 34(2), 241-246.
[http://dx.doi.org/10.20524/aog.2020.0566] [PMID: 33654366]
[10]
Lencioni, R.; de Baere, T.; Soulen, M.C.; Rilling, W.S.; Geschwind, J.F.H. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology, 2016, 64(1), 106-116.
[http://dx.doi.org/10.1002/hep.28453] [PMID: 26765068]
[11]
Marcacuzco, Q.A.; Nutu, O.A.; San Román, M.R.; Justo, A.I.; Calvo, P.J.; Manrique, M.A.; García-Sesma, Á.; Loinaz, S.C.; Caballero, M.J.; Romero, J.L.C. Complications of transarterial chemoembolization (TACE) in the treatment of liver tumors. Cir. Esp., 2018, 96(9), 560-567.
[http://dx.doi.org/10.1016/j.ciresp.2018.06.004]
[12]
Casadaban, L.C.; Minocha, J.; Bui, J.T.; Knuttinen, M.G.; Ray, C.E., Jr; Gaba, R.C. Conventional ethiodized oil transarterial chemoembolization for treatment of hepatocellular carcinoma: Contemporary single-center review of clinical outcomes. AJR Am. J. Roentgenol., 2016, 206(3), 645-654.
[http://dx.doi.org/10.2214/AJR.15.14758] [PMID: 26901023]
[13]
Freites-Martinez, A.; Santana, N.; Arias-Santiago, S.; Viera, A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr., 2021, 112(1), 90-92.
[http://dx.doi.org/10.1016/j.ad.2019.05.009]
[14]
Petruzzi, P.; Crocetti, L.; Lencioni, R. Chemoembolization of hepatocellular carcinoma. Semin. Intervent. Radiol., 2013, 30(1), 003-011.
[http://dx.doi.org/10.1055/s-0033-1333648] [PMID: 24436512]
[15]
Miyayama, S.; Matsui, O. Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: Rationale, technique, and outcome. J. Vasc. Interv. Radiol., 2016, 27(9), 1269-1278.
[http://dx.doi.org/10.1016/j.jvir.2016.04.014] [PMID: 27345337]
[16]
Miyayama, S.; Yamashiro, M.; Sugimori, N.; Ikeda, R.; Okimura, K.; Sakuragawa, N. Outcomes of patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization using guidance software. J. Vasc. Interv. Radiol., 2019, 30(1), 10-18.
[http://dx.doi.org/10.1016/j.jvir.2018.08.009] [PMID: 30580809]
[17]
Miyayama, S. Ultraselective conventional transarterial chemoembolization: When and how? Clin. Mol. Hepatol., 2019, 25(4), 344-353.
[http://dx.doi.org/10.3350/cmh.2019.0016] [PMID: 31022779]
[18]
Zhu, X.; Zhu, L.; Yang, R. Transcatheter arterial chemoembolization experience for advanced hepatocellular carcinoma with right atrial tumor thrombus. J. Cancer Res. Ther., 2019, 15(2), 305-311.
[http://dx.doi.org/10.4103/jcrt.JCRT_923_17] [PMID: 30964102]
[19]
Horn, C.C.; Wallisch, W.J.; Homanics, G.E.; Williams, J.P. Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. Eur. J. Pharmacol., 2014, 722, 55-66.
[http://dx.doi.org/10.1016/j.ejphar.2013.10.037] [PMID: 24495419]
[20]
Navari, R.M. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim. Biophys. Acta Biomembr., 2015, 1848(10), 2738-2746.
[http://dx.doi.org/10.1016/j.bbamem.2015.03.020] [PMID: 25838122]
[21]
Veiga-Gil, L.; Pueyo, J.; López-Olaondo, L. Postoperative nausea and vomiting: Physiopathology, risk factors, prophylaxis and treatment. Rev. Esp. Anestesiol. Reanim., 2017, 64(4), 223-232.
[http://dx.doi.org/10.1016/j.redare.2017.02.005]
[22]
Tateosian, V.S.; Champagne, K.; Gan, T.J. What is new in the battle against postoperative nausea and vomiting? Baillieres. Best Pract. Res. Clin. Anaesthesiol., 2018, 32(2), 137-148.
[http://dx.doi.org/10.1016/j.bpa.2018.06.005] [PMID: 30322455]
[23]
Son, J.; Yoon, H. Factors affecting postoperative nausea and vomiting in surgical patients. J. Perianesth. Nurs., 2018, 33(4), 461-470.
[http://dx.doi.org/10.1016/j.jopan.2016.02.012] [PMID: 30077290]
[24]
Aapro, M. CINV: Still troubling patients after all these years. Support. Care Cancer, 2018, 26(S1), 5-9.
[http://dx.doi.org/10.1007/s00520-018-4131-3] [PMID: 29556808]
[25]
Mosa, A.S.M.; Hossain, A.M.; Lavoie, B.J.; Yoo, I. Patient-related risk factors for chemotherapy-induced nausea and vomiting: A systematic review. Front. Pharmacol., 2020, 11, 329.
[http://dx.doi.org/10.3389/fphar.2020.00329] [PMID: 32296333]
[26]
Lu, H.; Zheng, C.; Liang, B.; Xiong, B. Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: A retrospective analysis. BMC Gastroenterol., 2021, 21(1), 256.
[http://dx.doi.org/10.1186/s12876-021-01839-w] [PMID: 34116638]
[27]
Sekine, I.; Segawa, Y.; Kubota, K.; Saeki, T. Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis. Cancer Sci., 2013, 104(6), 711-717.
[http://dx.doi.org/10.1111/cas.12146] [PMID: 23480814]
[28]
Neufeld, S.M.; Newburn-Cook, C.V. What are the risk factors for nausea and vomiting after neurosurgery? A systematic review. Can. J. Neurosci. Nurs., 2008, 30(1), 23-34.
[PMID: 18432079]
[29]
Kovac, A.L. Comparative pharmacology and guide to the use of the serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting. Drugs, 2016, 76(18), 1719-1735.
[http://dx.doi.org/10.1007/s40265-016-0663-3] [PMID: 27988869]
[30]
Balu, S.; Buchner, D.; Craver, C.; Gayle, J. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting. Clin. Ther., 2011, 33(4), 443-455.
[http://dx.doi.org/10.1016/j.clinthera.2011.04.009] [PMID: 21635990]
[31]
Gupta, K.; Singh, I.; Gupta, P.; Chauhan, H.; Jain, M.; Rastogi, B. Palonosetron, ondansetron, and granisetron for antiemetic prophylaxis of postoperative nausea and vomiting - a comparative evaluation. Anesth. Essays Res., 2014, 8(2), 197-201.
[http://dx.doi.org/10.4103/0259-1162.134503] [PMID: 25886226]
[32]
Tian, W.; Wang, Z.; Zhou, J.; Zhang, S.; Wang, J.; Chen, Q.; Huang, C.; Pan, L.; Zhang, L.; Huang, J.; Shen, H.; Lin, T. Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. Med. Oncol., 2011, 28(1), 71-78.
[http://dx.doi.org/10.1007/s12032-009-9398-2] [PMID: 20049561]
[33]
Parathoduvil, A.A.; Sisupalan, A.; Rema, P.L. Comparison of antiemetic effectiveness of palonosetron versus ondansetron in patients on cancer chemotherapy: A prospective observational study in South Indians. J. Clin. Diagn. Res., 2017, 11(5), FC10-FC14.
[http://dx.doi.org/10.7860/JCDR/2017/25129.9818] [PMID: 28658796]
[34]
Ueda, H.; Shimono, C.; Nishimura, T.; Shimamoto, M.; Yamaue, H. Palonosetron exhibits higher total control rate compared to first-generation serotonin antagonists and improves appetite in delayed-phase chemotherapy-induced nausea and vomiting. Mol. Clin. Oncol., 2014, 2(3), 375-379.
[http://dx.doi.org/10.3892/mco.2014.263] [PMID: 24772303]
[35]
Hahm, T.S.; Hwang, J.W.; Kim, W.H.; Oh, E.J.; Kim, D.K.; Choi, W.J.; Kim, Y.H.; Ryu, J.H.; Yoo, B.H.; Yon, J.H. A prospective, randomized, double-blind, multicenter trial to evaluate the therapeutic efficacy and safety of palonosetron in the treatment of postoperative nausea and vomiting over a 72-h period. J. Anesth., 2015, 29(1), 21-28.
[http://dx.doi.org/10.1007/s00540-014-1884-9] [PMID: 25037960]
[36]
Morganroth, J.; Flaharty, K.K.; Parisi, S.; Moresino, C. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: A double-blind, randomized, parallel group study in healthy volunteers. Support. Care Cancer, 2016, 24(2), 621-627.
[http://dx.doi.org/10.1007/s00520-015-2822-6] [PMID: 26111957]
[37]
Singh, P.M.; Borle, A.; Gouda, D.; Makkar, J.K.; Arora, M.K.; Trikha, A.; Sinha, A.; Goudra, B. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)—a meta-analysis. J. Clin. Anesth., 2016, 34, 459-482.
[http://dx.doi.org/10.1016/j.jclinane.2016.05.018] [PMID: 27687434]
[38]
Campos, G.O.; de Jesus, M.M.; Jesus, G.N.; de Oliveira, P.R.R.; Lessa, C.N.; de Oliveira Junior, J.C.M.F.; de Castro, A.L.J.S.; Alves, R.L.; Módolo, N.S.P. Palonosetron versus ondansetron for prevention of nausea and vomiting after total abdominal hysterectomy under spinal anesthesia with intrathecal morphine: A double-blind, randomized controlled trial. BMC Anesthesiol., 2019, 19(1), 159.
[http://dx.doi.org/10.1186/s12871-019-0830-7] [PMID: 31421679]
[39]
Ryu, J.H.; Jeon, Y.T.; Min, B.; Hwang, J.Y.; Sohn, H.M. Effects of palonosetron for prophylaxis of postoperative nausea and vomiting in high-risk patients undergoing total knee arthroplasty: A prospective, randomized, double-blind, placebo-controlled study. PLoS One, 2018, 13(5), e0196388.
[http://dx.doi.org/10.1371/journal.pone.0196388] [PMID: 29758039]
[40]
Yang, Y.; Zhang, L. A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting. Chin. Clin. Oncol. , 2020, 9(2), 17.
[http://dx.doi.org/10.21037/cco.2019.11.02] [PMID: 31865713]
[41]
Sento, S.; Kitamura, N.; Yamamoto, T.; Nakashiro, K.; Hamakawa, H.; Ibaragi, S.; Sasaki, A.; Takamaru, N.; Miyamoto, Y.; Kodani, I.; Ryoke, K.; Mishima, K.; Ueyama, Y. Palonosetron prevents highly emetogenic chemotherapyinduced nausea and vomiting in oral cancer patients. Anticancer Res., 2017, 37(12), 6977-6981.
[http://dx.doi.org/10.21873/anticanres.12165] [PMID: 29187483]
[42]
Schwartzberg, L.S.; McLaughlin, T.; Geller, R.B.; Gabrail, N.Y.; Marks, S.M. Real-world efficacy: Intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. J. Comp. Eff. Res., 2018, 7(12), 1161-1170.
[http://dx.doi.org/10.2217/cer-2018-0089] [PMID: 30304955]
[43]
Sakamoto, T.; Saito, Y.; Kobayashi, M.; Yamada, T.; Takekuma, Y.; Nakai, M.; Ogawa, K.; Iseki, K.; Sugawara, M. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. Support. Care Cancer, 2020, 28(7), 3251-3257.
[http://dx.doi.org/10.1007/s00520-019-05178-1] [PMID: 31732854]
[44]
Ikari, Y.; Ogata, K.; Nakashima, Y.; Sato, E.; Masaki, M.; Katsuya, H.; Goto, T.; Tanaka, T.; Ishitsuka, K.; Takamatsu, Y.; Hara, S.; Tamura, K. Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy. Support. Care Cancer, 2014, 22(7), 1959-1964.
[http://dx.doi.org/10.1007/s00520-014-2179-2] [PMID: 24590375]